Beckman Coulter Highlights Latest Innovations in Clinical Diagnostics at WHX Labs Dubai
Posted on 11 Feb 2026
Beckman Coulter Diagnostics (Brea, CA, USA) is showcasing its broad portfolio of laboratory analyzers and workflow solutions at WHX Labs Dubai 2026, demonstrating how continued innovation is helping laboratories deliver fast, consistent, and reliable diagnostic results.
At booth S2.G10, the company is spotlighting its featured product, the DxC 500i Clinical Analyzer, an integrated clinical chemistry and immunoassay system designed to maximize performance. The space-saving platform supports independently operating chemistry and immunoassay testing, reagent load-on-the-fly functionality, rapid throughput, and FlexMode Maintenance, enabling laboratories to maintain productivity even during peak workloads.
The DxC 500i delivers time to first results in as few as eight minutes for chemistry tests and 18 minutes for immunoassay panels such as β-hCG. Random access functionality helps accelerate priority samples, while a broad and expanding assay menu across chemistry and immunoassay provides a comprehensive view of disease states from a single analyzer. Standardized, right-sized reagent packs further support consistent, high-quality results while minimizing waste, backed by Six Sigma performance assays.
Also featured is the award-winning DxI 9000 Access Immunoassay Analyzer, which introduces first-of-its-kind high-sensitivity immunoassay testing for core laboratories. With throughput of up to 450 tests per hour, optimized reagent utilization, and enhanced traceability, the system is designed to accelerate time to answers while amplifying overall laboratory productivity. Real-time insights and high system availability help laboratories meet rising testing demands with confidence.
In addition to its diagnostic capabilities, the DxI 9000 is engineered to streamline laboratory operations. Its ZeroDaily Maintenance design eliminates the need for routine daily maintenance, reducing annual maintenance activities by up to 96% and allowing staff to focus more time on testing and patient care.
Related Links:
Beckman Coulter